Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Please Try Again

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

News Focus

LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)

Bullboard - Stock Discussion Forum Eli Lilly and Co LLY

Healthcare

Eli Lilly and Company is a medicine company. The Company discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Mounjaro, Trulicity and Zepbound. Its oncology products include Alimta, Retevmo, Tyvyt and Verzenio. Its immunology products include Ebglyss, Olumiant... see more

Add To Watchlist

Bullboard (NYSE:LLY)

View:

Post by whytestockson Nov 18, 2024 9:45pm

Lilly's muvalaplin lowered lipoprotein(a) levels in adults w

Just In: $LLY Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested doseLilly's muvalaplin lowered lipoprotein(a ...more

Post by whytestockson Nov 17, 2024 7:01am

Prediction: 3 Stocks That'll Be Worth More Than Tesla 10 Yea

BREAKING NEWS: $LLY Prediction: 3 Stocks That'll Be Worth More Than Tesla 10 Years From Now2024-11-17 06:42:00 ET Tesla (NASDAQ: TSLA) is back. Shares of the electric vehicle (EV) maker plunged as ...more

Pharmaceutical Tech Co Reports 2.7X Revenue Growth Year-Over-Year at US $24 Million

posted Nov 21, 2024 9:00am by Innocan Pharma Corp

"Our strong operational and financial momentum continued throughout 2024 and now in the third quarter, we again demonstrated solid financial results. We are pleased to report nine consecutive quarters of continuous revenue growth. Our online platform continues to perform exceptionally well, contributing to our strong nine-month revenue growth of 174% YoY ...read more

Post by whytestockson Oct 30, 2024 7:00pm

A Once-in-a-Decade Investment Opportunity: 1 Pharmaceutical

News; $LLY A Once-in-a-Decade Investment Opportunity: 1 Pharmaceutical Stock to Buy Now Hand Over Fist and Hold for Years2024-10-30 04:45:00 ET For the past couple of years, two of the biggest themes ...more

(0)
•••

Post by PressReleaseon Oct 02, 2024 7:30am

New Press Release - Lilly announces new $4.5 billion site - the Lilly Medicine Foundry - to drive innovation in drug production and make medicines for clinical trials

Indiana facility will combine research, manufacturing and the latest technology to innovate new production methods and scale global access to clinical supply for Lilly's growing pipeline Opening in late 2027, the facility will increase Lilly's total capital commitment in the United States to more...read article.

Post by whytestockson Sep 28, 2024 5:30am

Got $1,000? 2 Superior Growth Stocks to Buy and Hold Forever

JUST IN: $LLY Got $1,000? 2 Superior Growth Stocks to Buy and Hold Forever2024-09-28 05:15:00 ET In the stock market, ups and downs are inevitable. But long-term investors shouldn't get wrapped up ...more

247

(0)
•••

Post by PressReleaseon Sep 25, 2024 6:45am

New Press Release - New data show Lilly's EBGLYSS(TM) (lebrikizumab-lbkz) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitis

Monthly EGBLYSS maintenance dosing sustained clear or almost-clear skin for up to three years in the vast majority of ADvocate 1 and 2 responders Nearly 87 percent of patients taking EBGLYSS did not require either high-potency topical corticosteroids or systemic treatments during the three-year...read article.

(0)
•••

Post by PressReleaseon Sep 24, 2024 6:00am

New Press Release - Lilly's Kisunla(TM) (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic Alzheimer's Disease

Japan is the second major market where Kisunla has received approvalKisunla was first approved in the United States in July 2024INDIANAPOLIS, Sept. 24, 2024 /PRNewswire/ -- The Ministry of Health, Labour and Welfare Japan has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks...read article.

(0)
•••

Post by PressReleaseon Sep 13, 2024 4:08pm

New Press Release - FDA Approves Lilly's EBGLYSS(TM) (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis

EBGLYSS provides a new first-line biologic treatment for moderate-to-severe atopic dermatitis that is not well controlled with topicalsPatients treated with EBGLYSS experienced significant skin clearance as early as four weeks and meaningful itch relief as early as two weeksEBGLYSS delivers long...read article.

(0)
•••

Post by PressReleaseon Sep 12, 2024 5:30am

New Press Release - Lilly expands manufacturing footprint in Ireland with $1.8 billion investment

Company ups manufacturing investment in Limerick by $1 billion; unveils new $800 million Kinsale facilityNew investment will enhance global medicine production, benefiting millions of patients worldwideINDIANAPOLIS, Sept. 12, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced...read article.

(0)
•••

Post by PressReleaseon Sep 10, 2024 11:57am

New Press Release - With once-a-week dosing, insulin efsitora alfa delivers similar A1C reduction compared to daily insulin in adults with type 1 diabetes

Detailed results were published in The Lancet and simultaneously presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2024INDIANAPOLIS, Sept. 10, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from the QWINT-5 phase 3 trial...read article.

(0)
•••

Post by PressReleaseon Sep 10, 2024 11:19am

New Press Release - Once-weekly dose of insulin efsitora alfa delivers A1C reduction consistent with the most advanced daily insulin in people with type 2 diabetes

In QWINT-2, efsitora helped adults naïve to insulin therapy currently using and not using GLP-1 receptor agonists achieve an A1C below 7% Detailed results were published in The New England Journal of Medicine and simultaneously presented at the European Association for the Study of Diabetes (EASD...read article.

(0)
•••

Post by PressReleaseon Sep 09, 2024 6:45am

New Press Release - Lilly appoints Lucas Montarce as executive vice president and chief financial officer

INDIANAPOLIS, Sept. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the appointment of Lucas Montarce as executive vice president and chief financial officer (CFO) and member of the company's Executive Committee, effective immediately.Since joining Lilly in 2001...read article.

(0)
•••

Post by PressReleaseon Sep 05, 2024 6:45am

New Press Release - In a first-of-its-kind fixed dose study, once weekly insulin efsitora alfa leads to A1C reduction similar to daily insulin

In the phase 3 study, QWINT-1, efsitora was administered via four fixed doses once weekly in a single-use autoinjector in people with type 2 diabetes using basal insulin for the first timeIn a second phase 3 study, QWINT-3, efsitora also delivered non-inferior A1C reduction compared to daily...read article.

(0)
•••

Post by PressReleaseon Sep 04, 2024 6:00am

New Press Release - Lilly and EVA Pharma collaborate to expand access to baricitinib in low- to middle-income countries

Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases across 49 low- to middle-income countries in AfricaINDIANAPOLIS and CAIRO, Sept. 4, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and...read article.

Post by whytestockson Aug 30, 2024 4:33pm

Think Eli Lilly Stock Has Peaked? These 10 Words From the CE

News; $LLY Think Eli Lilly Stock Has Peaked? These 10 Words From the CEO May Change Your Mind2024-08-30 07:45:00 ET Eli Lilly (NYSE: LLY) stock is up a mammoth 770% in five years. It is trading at new ...more

339

The Market Update

< Previous bulletin

Next bulletin >

A daily snapshot of everything
from market open to close.

< Previous

Next >

Dealroom for high-potential pre-IPO opportunities

Become a member today, It's free!

Bullboard - Stock Discussion Forum Eli Lilly and Co LLY

Bullboard (NYSE:LLY)

Lilly's muvalaplin lowered lipoprotein(a) levels in adults w

Prediction: 3 Stocks That'll Be Worth More Than Tesla 10 Yea

Pharmaceutical Tech Co Reports 2.7X Revenue Growth Year-Over-Year at US $24 Million

A Once-in-a-Decade Investment Opportunity: 1 Pharmaceutical

New Press Release - Lilly announces new $4.5 billion site - the Lilly Medicine Foundry - to drive innovation in drug production and make medicines for clinical trials

Got $1,000? 2 Superior Growth Stocks to Buy and Hold Forever

New Press Release - New data show Lilly's EBGLYSS(TM) (lebrikizumab-lbkz) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitis

New Press Release - Lilly's Kisunla(TM) (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic Alzheimer's Disease

New Press Release - FDA Approves Lilly's EBGLYSS(TM) (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis

New Press Release - Lilly expands manufacturing footprint in Ireland with $1.8 billion investment

New Press Release - With once-a-week dosing, insulin efsitora alfa delivers similar A1C reduction compared to daily insulin in adults with type 1 diabetes

New Press Release - Once-weekly dose of insulin efsitora alfa delivers A1C reduction consistent with the most advanced daily insulin in people with type 2 diabetes

New Press Release - Lilly appoints Lucas Montarce as executive vice president and chief financial officer

New Press Release - In a first-of-its-kind fixed dose study, once weekly insulin efsitora alfa leads to A1C reduction similar to daily insulin

New Press Release - Lilly and EVA Pharma collaborate to expand access to baricitinib in low- to middle-income countries

Think Eli Lilly Stock Has Peaked? These 10 Words From the CE

Featured News Links

Discover Options Trading Strategies to Minimize your Tax Burden

Become a member today, It's free!

Sign In

Send my password

Become a member today, It's free!

Bullboard - Stock Discussion Forum Eli Lilly and Co LLY

Join the community and start posting on the bullboards today. It's free.

Create a portfolio watchlist today. It's free.

Bullboard (NYSE:LLY)

Featured News Links